Fiche publication
Date publication
février 2022
Journal
Cardiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Sharma A, Razaghizad A, Ferreira JP, Machu JL, Bozec E, Girerd N, Rossignol P, Zannad F
Lien Pubmed
Résumé
Background We used data from participants initially free of clinical cardiovascular disease in the STANISLAS cohort to evaluate the association between metabolic syndrome (MS) and development of preclinical heart failure (HF). Methods and Results The STANISLAS cohort is a single-center familial longitudinal cohort composed of 1006 families from the Nancy region of France (median follow-up of 17 years [1993-2016]). Age and sex matched logistic regression models and inverse probability weighting models were used to determine the association of MS and preclinical HF. Among 944 adult patients at the final visit, those with baseline MS, compared to patients who developed MS and those without MS, were more likely to be older (63 vs 61 vs 59 years of age) and male (73% vs 55% vs 45%). The risk of preclinical HF was numerically increased, compared to patients without MS, among patients who developed MS (adjusted odds ratio [aOR] 1.56, 95% CI 1.00-2.43) and patients with MS at baseline (aOR 2.27, 95% CI 1.07-4.81). Among the individual components of MS, the risk of preclinical HF was elevated in individuals with baseline hypertension (aOR 3.19, 95% CI 1.80-5.63) and baseline elevated waist circumference (aOR 2.59, 95% CI 1.47-4.57). Conclusion Given the high risk of mortality when patients with metabolic syndrome or elevated fasting glucose become established with HF failure, HF prevention remains an important public health concern. Evaluation of early aggressive lifestyle and possibly medical intervention among patients free of cardiovascular disease with an obese-hypertensive phenotype to prevent future HF development is warranted.
Référence
Cardiology. 2022 Feb 23;:
